44,223 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by PSP Research LLC

PSP Research LLC purchased a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 44,223 shares of the company’s stock, valued at approximately $534,000.

Several other institutional investors have also modified their holdings of AMLX. Aster Capital Management DIFC Ltd acquired a new stake in Amylyx Pharmaceuticals during the third quarter valued at approximately $48,000. California State Teachers Retirement System acquired a new stake in Amylyx Pharmaceuticals during the second quarter valued at approximately $28,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Amylyx Pharmaceuticals by 54.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after buying an additional 1,890 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Amylyx Pharmaceuticals by 433.2% during the second quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after buying an additional 5,904 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in Amylyx Pharmaceuticals during the second quarter valued at approximately $47,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Trading Down 0.9%

Shares of Amylyx Pharmaceuticals stock opened at $12.74 on Wednesday. The business’s 50 day simple moving average is $15.24 and its 200-day simple moving average is $14.22. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -8.49 and a beta of -0.11. Amylyx Pharmaceuticals, Inc. has a twelve month low of $4.64 and a twelve month high of $18.60.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Sell-side analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.39 earnings per share for the current year.

Analyst Ratings Changes

AMLX has been the topic of several research reports. Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Stifel Nicolaus initiated coverage on Amylyx Pharmaceuticals in a research note on Tuesday, March 3rd. They set a “buy” rating and a $21.00 price objective on the stock. Bank of America upped their price objective on Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, May 8th. Finally, HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.